期刊文献+

基于Hypogen药效团模型发现潜在的PTP1B抑制剂

Explore potential PTP1B inhibitors based on the Hypogen pharmacophore model
原文传递
导出
摘要 目的采用计算机辅助药物设计的方法发现潜在的PTP1B抑制剂。方法应用3D-QSAR药效团模型中的Hypogen模块构建药效团模型,成本分析、测试集预测和Fisher检验3种方法来验证该模型可用于预测化合物的生物活性的能力。运用该药效团模型对ZINC数据库进行虚拟筛选,得到Fit value值较高的先导化合物ZINC35671983。根据药效团的特征对ZINC35671983进行结构改造得到相应化合物。将化合物用ADMET进行成药预测。结果ZINC35671983进行结构改造筛选获得92个化合物,筛出对接得分高于ZINC3567198的8个化合物。结论发现8个潜在的PTP1B抑制剂,这有助于发现新的PTP1B先导化合物。 Objective To identify Potential PTP1B inhibitors by computer-aided drug design.Methods The Hypogen module of 3DQSAR pharmacophore model was used to construct the pharmacophore model,cost analysis,test set prediction and Fisher test to verify the ability of the model to predict the biological activity of the compound.The lead compound ZINC35671983 with high Fit value was obtained by virtual screening of ZINC database with the pharmacophore model.The corresponding compounds were obtained by structural modification of ZINC35671983 according to the characteristics of pharmacophore.The compounds were predicted by ADMET.Results ZINC35671983 obtained 92 compounds through structural modification screening,and screened out 8 compounds with higher docking scores than ZINC3567198.Conclusion A total of 8 potential PTP1B inhibitors were found which is helpful to find new PTP1B lead compounds.
作者 晋文燕 赵振宇 JIN Wen-yan;ZHAO Zhen-yu(Tianjin Key Laboratory of Metabolic Diseases,NHC Key Laboratory of Hormones and Development,Chu Hsien-I Memorial Hospital&Tianjin Institute of Endocrinology,Tianjin Medical University,Tianjin 300134,China)
出处 《现代药物与临床》 CAS 2023年第9期2175-2183,共9页 Drugs & Clinic
基金 天津市医学重点学科(专科)建设资助项目(TJYXZDXK-032A)。
关键词 PTP1B抑制剂 药效团 分子对接 成本分析 测试集预测 PTP1B inhibitors pharmacophore molecules docking cost analysis test set prediction
  • 相关文献

参考文献5

二级参考文献32

  • 1庄奕宏.阴茎癌患者血清可溶性肿瘤坏死因子受体水平与人乳头瘤病毒感染的研究[J].医师进修杂志(外科版),2005,28(10):18-19. 被引量:1
  • 2Sun JF, Liu HJ, Li C. Relalionship between expressions of EphlM with angiogenesis in Iluman coiorectal carcinoma[ J ].医药前沿,2013,5(21):250-255.
  • 3Bardelle C, Cross D, Davevlport S,et al. Inhibitors of the tyrosine kinase EphB4. Part I :structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines [ J ]. Biotrg Med Chem Lett ,2008,18 (2) :2776 - 2780.
  • 4Bardelle C, Coleman T, Cross D, et al. Inhibitov of the tyrosine kinase EphB4. Part 2:strueture-based discovery and optimisation of 3,5-his substituted anilinopyrimidines [ J ]. Bioorg Med Chem Lett,2008,18(5 ) :5717 -5721.
  • 5Barlaam B, Ducray R, Read J, et al. |nhibitors of the tyrosine kinase EphB4. Part 4: discovery and optimization of a benzylic alcohol series[ J ]. Bioorg Med Chem Lett ,2011,21 ( 22 ) :2207 - 2211.
  • 6Lafleur K, Huang D, Zhou T,et al. Stnwture-based optimization of potent and selective inhibitors of the tyrosine kinase en.,thropoi- e/in producing human hepatoeellular carcinoma receptor IM ( EphlM ) [ J ]. J Med Chem ,2009,52 ( 6 ) :6435 - 6446.
  • 7Lafleur K, Dong J, Huang D, et cal. Optimization of inhibitors of the tyrosine kinase EphlM. 2. Cellular poteney improvement and binding mode validation by X-ray crystallography [ J ]. J Med Cbem ,2013,56( 1 ) :84 -96.
  • 8Miyazaki Y, Nakano M,Sato M,et al. l)esign and effective syn- thesis of novel templates,3,7-diphenyl-4-amino-thieno and furo- [ 3,2-c] pyridines as protein kinase inhibitors and in vitro evalu- ation targeting angiogenetie kinases [ J ]. Bioorg Med Chem Lett, 2007,17 ( 2 ) :250 - 254.
  • 9Mitchell SA, Danea MD, Blomgren PA, et al. lmidazo[1,2-a ] pyrazine diaryl mas: inhibito of the receptor tyrosine kinase EphB4[ J]. Bioorg Med Cbem l.ett,2009,19( 6 ) :6991 -6995.
  • 10Fischer R. The Principle of Experimentation, Illustrated by a Psy- cho-Physical Experiment, in the De.ign oJ" Experiments [ M ]. New York : Hafner Publishing Company, 1966 : 129 - 153.

共引文献2772

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部